Canaccord Genuity Starts MAP Pharmaceuticals (MAPP) at Buy
MAPP Hot Sheet
Rating Summary:3 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Canaccord Genuity initiates coverage on MAP Pharmaceuticals (NASDAQ: MAPP) with a Buy. PT $24.00.
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $14.04 yesterday, with a 52 week range of $10.54-$17.35.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $14.04 yesterday, with a 52 week range of $10.54-$17.35.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Appointment of Scott R. Ward as Creganna-Tactx Medical Chairman
- Citi, Oppenheimer, William Blair Starts Acquity (AQ) at Buy/Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Genuity Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
